Shopping Cart 0
Cart Subtotal
USD 0

Cellectar Biosciences Inc (CLRB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Cellectar Biosciences Inc (Cellectar) develops phospholipid drug conjugates (PDCs) for the treatment and diagnosis of cancer. Its lead product, CLR 131, is a small-molecule radiotherapeutic PDC, being developed for the treatment of relapse or refractory multiple myeloma. Cellectar's other products in pipeline include CLR 125, CLR 1602-PTX, CLR 124 and CLR 1502. The pipeline also includes diagnostic and optical imaging assets. Cellectar explores the creation of additional PDCs under its CLR CTX Chemotherapeutic PDC program. It offers PDC's for the treatment of multiple myeloma, micrometastatic disease, glioma and breast cancer lumpectomy. The company's products are based on a cancer targeting delivery and retention platform of optimized phospholipid ether analogs (PLEs). Cellectar is headquartered in Madison, Wisconsin, the US.

Cellectar Biosciences Inc (CLRB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Cellectar Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 10

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Cellectar Biosciences and Orano Med Enter into Co-Development Agreement 12

Cellectar Biosciences Enters into Agreement with Onconova Therapeutics 13

Cellectar Biosciences Enters into Research Agreement with Avicenna Oncology 14

Cellectar Biosciences Enters into Agreement with INC Research 15

Cellectar Biosciences Enters into Contract with National Cancer Institute 16

Cellectar Biosciences Extends Agreement with Pierre Fabre Lab 17

Licensing Agreements 18

Cellectar Biosciences Enters into Licensing Agreement with Wisconsin Alumni Research Foundation 18

Equity Offering 19

Cellectar Biosciences Raises USD16.5 Million in Public Offering of Shares 19

Cellectar Biosciences Raises USD7.7 Million in Private Placement of Shares 21

Cellectar Biosciences Completes Public Offering of Shares for USD9.2 Million 22

Cellectar Biosciences to Raise Funds through Private Placement of Shares upon Exercise of Warrants 24

Cellectar Biosciences Raises USD8 Million in Public Offering of Shares and Warrants 25

Cellectar Biosciences Raises USD3.3 Million in Public Offering of Shares 27

Cellectar Biosciences Raises USD13.5 Million in Public Offering of Common Stock and Warrants 29

Novelos Therapeutics Completes Public Offering Of Units For USD 5.5 Million 31

Novelos Therapeutics Completes Private Placement Of Common Stock For USD 2 Million 32

Novelos Therapeutics Completes Private Placement Of Shares For USD 1 Million Upon Exercise Of Warrants 33

Novelos Therapeutics Completes Private Placement Of Units For USD 5.4 Million 34

Debt Offering 35

Novelos Therapeutics Completes Private Placement Of Debentures Due 2016 For USD 4 Million 35

Cellectar Biosciences Inc-Key Competitors 36

Cellectar Biosciences Inc-Key Employees 37

Cellectar Biosciences Inc-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 39

Financial Announcements 39

Aug 10, 2018: Cellectar reports 2018 second quarter financial results and provides business update 39

May 11, 2018: Cellectar Reports Recent Corporate Highlights and 2018 First Quarter Financial Results 41

Mar 21, 2018: Cellectar Reports 2017 Financial Results and Provides a Corporate Update 42

Nov 09, 2017: Cellectar Biosciences Reports Third Quarter 2017 Financial and Corporate Performance 43

Aug 14, 2017: Cellectar Biosciences Reports Second Quarter 2017 Financial and Corporate Performance 44

May 11, 2017: Cellectar Biosciences Reports First Quarter 2017 Financial and Corporate Performance 45

Mar 15, 2017: Cellectar Biosciences Reports 2016 Company Performance and Continued Progress in First Quarter 2017 46

Mar 15, 2017: Cellectar Biosciences annual net loss increases 47

Corporate Communications 48

Apr 04, 2018: Cellectar Biosciences Appoints Brian M. Posner as Chief Financial Officer 48

Sep 18, 2017: Cellectar Biosciences Appoints Jarrod Longcor Chief Business Officer 49

Apr 21, 2017: UPDATED: Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer 50

Apr 12, 2017: Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer 51

Apr 10, 2017: Cellectar Biosciences Adds Industry Veterans Douglas Swirsky and Frederick Driscoll to Its Board of Directors 52

Product News 53

Jan 31, 2017: Cellectar Biosciences Announces Two Peer Reviewed Studies Demonstrating the Capabilities of the PDC Platform 53

01/26/2017: Cellectar Biosciences to Present at NobleCon13 54

01/05/2017: Cellectar Biosciences to Present at the 9th Annual Biotech Showcase 55

Product Approvals 56

Dec 14, 2017: Cellectar Files IND for Phase 1 Trial of CLR 131 in Pediatric Cancers 56

Clinical Trials 57

Dec 06, 2017: Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort in Phase II Trial of CLR 131 57

Nov 07, 2017: Cellectar Announces Updated Median Overall Survival of 26.2 Months from Cohort 1 of CLR 131 Phase 1 Trial in Advanced Multiple Myeloma 58

Oct 30, 2017: New Preclinical Data Suggest That Cellectar Biosciences' PDC Platform Provides Enhanced Outcomes in Combination with External Radiation 59

Oct 24, 2017: Cellectar Biosciences Introduces Multiple Dose Regimen in Fifth Cohort of Phase 1 Trial of CLR 131 in Multiple Myeloma 60

Sep 27, 2017: Cellectar Biosciences Reports Cohort Four Data and Partial Response in Relapsed or Refractory Multiple Myeloma Patient Treated with CLR 131 61

Aug 08, 2017: Cellectar Biosciences' CLR 131 Achieves Overall Survival of Greater Than 22 Months in Advanced Multiple Myeloma Patients 62

May 18, 2017: Three Abstracts on Dosing Regimens of Cellectar's CLR 131 in a Variety of Tumor Types Published in the 2017 ASCO Annual Meeting Proceedings 64

Apr 27, 2017: Cellectar's Radiotherapeutic investigational compound CLR 131 Demonstrate an Increased Survival Benefit Using Multiple Doses in Preclinical Studies 65

Mar 30, 2017: After Much Anticipation, Cellectar Biosciences Initiates NCI-Supported Phase II Trial of CLR 131 in Multiple Myeloma and Other Blood Cancers 66

Feb 27, 2017: Cellectar Biosciences Provides Phase I Trial Update of CLR 131 in Multiple Myeloma: Median Progression-Free Survival Extends to 133 Days, Median Overall Survival Reaches 17.7 Months 67

Feb 22, 2017: Upon Successful Completion of Cohort 3, Cellectar Biosciences Initiates Fourth Cohort of Its Phase I Clinical Trial of CLR 131 in Multiple Myeloma 69

Other Significant Developments 70

Oct 10, 2017: Cellectar Biosciences and Pierre Fabre Extend Collaboration for Development of New Phospholipid Drug Conjugates 70

Appendix 71

Methodology 71

About GlobalData 71

Contact Us 71

Disclaimer 71


List Of Figure

List of Figures

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Cellectar Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cellectar Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Cellectar Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 10

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Cellectar Biosciences and Orano Med Enter into Co-Development Agreement 12

Cellectar Biosciences Enters into Agreement with Onconova Therapeutics 13

Cellectar Biosciences Enters into Research Agreement with Avicenna Oncology 14

Cellectar Biosciences Enters into Agreement with INC Research 15

Cellectar Biosciences Enters into Contract with National Cancer Institute 16

Cellectar Biosciences Extends Agreement with Pierre Fabre Lab 17

Cellectar Biosciences Enters into Licensing Agreement with Wisconsin Alumni Research Foundation 18

Cellectar Biosciences Raises USD16.5 Million in Public Offering of Shares 19

Cellectar Biosciences Raises USD7.7 Million in Private Placement of Shares 21

Cellectar Biosciences Completes Public Offering of Shares for USD9.2 Million 22

Cellectar Biosciences to Raise Funds through Private Placement of Shares upon Exercise of Warrants 24

Cellectar Biosciences Raises USD8 Million in Public Offering of Shares and Warrants 25

Cellectar Biosciences Raises USD3.3 Million in Public Offering of Shares 27

Cellectar Biosciences Raises USD13.5 Million in Public Offering of Common Stock and Warrants 29

Novelos Therapeutics Completes Public Offering Of Units For USD 5.5 Million 31

Novelos Therapeutics Completes Private Placement Of Common Stock For USD 2 Million 32

Novelos Therapeutics Completes Private Placement Of Shares For USD 1 Million Upon Exercise Of Warrants 33

Novelos Therapeutics Completes Private Placement Of Units For USD 5.4 Million 34

Novelos Therapeutics Completes Private Placement Of Debentures Due 2016 For USD 4 Million 35

Cellectar Biosciences Inc, Key Competitors 36

Cellectar Biosciences Inc, Key Employees 37

Cellectar Biosciences Inc, Subsidiaries 38

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Cellectar Biosciences Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Cellectar Biosciences Inc (Cellectar) develops phospholipid drug conjugates (PDCs) for the treatment and diagnosis of cancer. Its lead product, CLR 131, is a small-molecule radiotherapeutic PDC, being developed for the treatment of relapse or refractory multiple myeloma. Cellectar's other products in pipeline include CLR 125, CLR 1602-PTX, CLR 124 and CLR 1502. The pipeline also includes diagnostic and optical imaging assets. Cellectar explores the creation of additional PDCs under its CLR CTX Chemotherapeutic PDC program. It offers PDC's for the treatment of multiple myeloma, micrometastatic disease, glioma and breast cancer lumpectomy. The company's products are based on a cancer targeting delivery and retention platform of optimized phospholipid ether analogs (PLEs). Cellectar is headquartered in Madison, Wisconsin, the US.

Cellectar Biosciences Inc (CLRB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Cellectar Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 10

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Cellectar Biosciences and Orano Med Enter into Co-Development Agreement 12

Cellectar Biosciences Enters into Agreement with Onconova Therapeutics 13

Cellectar Biosciences Enters into Research Agreement with Avicenna Oncology 14

Cellectar Biosciences Enters into Agreement with INC Research 15

Cellectar Biosciences Enters into Contract with National Cancer Institute 16

Cellectar Biosciences Extends Agreement with Pierre Fabre Lab 17

Licensing Agreements 18

Cellectar Biosciences Enters into Licensing Agreement with Wisconsin Alumni Research Foundation 18

Equity Offering 19

Cellectar Biosciences Raises USD16.5 Million in Public Offering of Shares 19

Cellectar Biosciences Raises USD7.7 Million in Private Placement of Shares 21

Cellectar Biosciences Completes Public Offering of Shares for USD9.2 Million 22

Cellectar Biosciences to Raise Funds through Private Placement of Shares upon Exercise of Warrants 24

Cellectar Biosciences Raises USD8 Million in Public Offering of Shares and Warrants 25

Cellectar Biosciences Raises USD3.3 Million in Public Offering of Shares 27

Cellectar Biosciences Raises USD13.5 Million in Public Offering of Common Stock and Warrants 29

Novelos Therapeutics Completes Public Offering Of Units For USD 5.5 Million 31

Novelos Therapeutics Completes Private Placement Of Common Stock For USD 2 Million 32

Novelos Therapeutics Completes Private Placement Of Shares For USD 1 Million Upon Exercise Of Warrants 33

Novelos Therapeutics Completes Private Placement Of Units For USD 5.4 Million 34

Debt Offering 35

Novelos Therapeutics Completes Private Placement Of Debentures Due 2016 For USD 4 Million 35

Cellectar Biosciences Inc-Key Competitors 36

Cellectar Biosciences Inc-Key Employees 37

Cellectar Biosciences Inc-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 39

Financial Announcements 39

Aug 10, 2018: Cellectar reports 2018 second quarter financial results and provides business update 39

May 11, 2018: Cellectar Reports Recent Corporate Highlights and 2018 First Quarter Financial Results 41

Mar 21, 2018: Cellectar Reports 2017 Financial Results and Provides a Corporate Update 42

Nov 09, 2017: Cellectar Biosciences Reports Third Quarter 2017 Financial and Corporate Performance 43

Aug 14, 2017: Cellectar Biosciences Reports Second Quarter 2017 Financial and Corporate Performance 44

May 11, 2017: Cellectar Biosciences Reports First Quarter 2017 Financial and Corporate Performance 45

Mar 15, 2017: Cellectar Biosciences Reports 2016 Company Performance and Continued Progress in First Quarter 2017 46

Mar 15, 2017: Cellectar Biosciences annual net loss increases 47

Corporate Communications 48

Apr 04, 2018: Cellectar Biosciences Appoints Brian M. Posner as Chief Financial Officer 48

Sep 18, 2017: Cellectar Biosciences Appoints Jarrod Longcor Chief Business Officer 49

Apr 21, 2017: UPDATED: Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer 50

Apr 12, 2017: Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer 51

Apr 10, 2017: Cellectar Biosciences Adds Industry Veterans Douglas Swirsky and Frederick Driscoll to Its Board of Directors 52

Product News 53

Jan 31, 2017: Cellectar Biosciences Announces Two Peer Reviewed Studies Demonstrating the Capabilities of the PDC Platform 53

01/26/2017: Cellectar Biosciences to Present at NobleCon13 54

01/05/2017: Cellectar Biosciences to Present at the 9th Annual Biotech Showcase 55

Product Approvals 56

Dec 14, 2017: Cellectar Files IND for Phase 1 Trial of CLR 131 in Pediatric Cancers 56

Clinical Trials 57

Dec 06, 2017: Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort in Phase II Trial of CLR 131 57

Nov 07, 2017: Cellectar Announces Updated Median Overall Survival of 26.2 Months from Cohort 1 of CLR 131 Phase 1 Trial in Advanced Multiple Myeloma 58

Oct 30, 2017: New Preclinical Data Suggest That Cellectar Biosciences' PDC Platform Provides Enhanced Outcomes in Combination with External Radiation 59

Oct 24, 2017: Cellectar Biosciences Introduces Multiple Dose Regimen in Fifth Cohort of Phase 1 Trial of CLR 131 in Multiple Myeloma 60

Sep 27, 2017: Cellectar Biosciences Reports Cohort Four Data and Partial Response in Relapsed or Refractory Multiple Myeloma Patient Treated with CLR 131 61

Aug 08, 2017: Cellectar Biosciences' CLR 131 Achieves Overall Survival of Greater Than 22 Months in Advanced Multiple Myeloma Patients 62

May 18, 2017: Three Abstracts on Dosing Regimens of Cellectar's CLR 131 in a Variety of Tumor Types Published in the 2017 ASCO Annual Meeting Proceedings 64

Apr 27, 2017: Cellectar's Radiotherapeutic investigational compound CLR 131 Demonstrate an Increased Survival Benefit Using Multiple Doses in Preclinical Studies 65

Mar 30, 2017: After Much Anticipation, Cellectar Biosciences Initiates NCI-Supported Phase II Trial of CLR 131 in Multiple Myeloma and Other Blood Cancers 66

Feb 27, 2017: Cellectar Biosciences Provides Phase I Trial Update of CLR 131 in Multiple Myeloma: Median Progression-Free Survival Extends to 133 Days, Median Overall Survival Reaches 17.7 Months 67

Feb 22, 2017: Upon Successful Completion of Cohort 3, Cellectar Biosciences Initiates Fourth Cohort of Its Phase I Clinical Trial of CLR 131 in Multiple Myeloma 69

Other Significant Developments 70

Oct 10, 2017: Cellectar Biosciences and Pierre Fabre Extend Collaboration for Development of New Phospholipid Drug Conjugates 70

Appendix 71

Methodology 71

About GlobalData 71

Contact Us 71

Disclaimer 71


List Of Figure

List of Figures

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Cellectar Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cellectar Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Cellectar Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 10

Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Cellectar Biosciences and Orano Med Enter into Co-Development Agreement 12

Cellectar Biosciences Enters into Agreement with Onconova Therapeutics 13

Cellectar Biosciences Enters into Research Agreement with Avicenna Oncology 14

Cellectar Biosciences Enters into Agreement with INC Research 15

Cellectar Biosciences Enters into Contract with National Cancer Institute 16

Cellectar Biosciences Extends Agreement with Pierre Fabre Lab 17

Cellectar Biosciences Enters into Licensing Agreement with Wisconsin Alumni Research Foundation 18

Cellectar Biosciences Raises USD16.5 Million in Public Offering of Shares 19

Cellectar Biosciences Raises USD7.7 Million in Private Placement of Shares 21

Cellectar Biosciences Completes Public Offering of Shares for USD9.2 Million 22

Cellectar Biosciences to Raise Funds through Private Placement of Shares upon Exercise of Warrants 24

Cellectar Biosciences Raises USD8 Million in Public Offering of Shares and Warrants 25

Cellectar Biosciences Raises USD3.3 Million in Public Offering of Shares 27

Cellectar Biosciences Raises USD13.5 Million in Public Offering of Common Stock and Warrants 29

Novelos Therapeutics Completes Public Offering Of Units For USD 5.5 Million 31

Novelos Therapeutics Completes Private Placement Of Common Stock For USD 2 Million 32

Novelos Therapeutics Completes Private Placement Of Shares For USD 1 Million Upon Exercise Of Warrants 33

Novelos Therapeutics Completes Private Placement Of Units For USD 5.4 Million 34

Novelos Therapeutics Completes Private Placement Of Debentures Due 2016 For USD 4 Million 35

Cellectar Biosciences Inc, Key Competitors 36

Cellectar Biosciences Inc, Key Employees 37

Cellectar Biosciences Inc, Subsidiaries 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Cellectar Biosciences Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.